Evaluation of a Long-circulating PSMA-targeting Peptide in a Xenograft Model of Bone Metastatic Prostate Cancer.

被引：0
|
作者：
Lo, W. [1 ]
Huang, Y. [1 ]
Chen, M. [1 ]
Lu, A. [1 ]
Wang, S. [1 ]
Chen, L. [1 ]
Farn, S. [1 ]
机构：
[1] Inst Nucl Energy Res, Taoyuan, Taiwan
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0029
引用
收藏
页码：S442 / S442
页数：1
相关论文
共 50 条
  • [21] Performance of a blood-based liquid biopsy test to detect PSMA expression on circulating tumor cells in men with metastatic prostate cancer.
    Gupta, Santosh
    Hamid, Anis
    Fernandez, Luisa
    Pasam, Anupama
    Lam, Ernest
    Tubbs, Alisa
    Bourdon, David
    Emmett, Louise
    Joshua, Anthony M.
    Hofman, Michael S.
    Wenstrup, Rick
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [22] Radium-223 demonstrates increased antitumor activity in combination with 177Lu-PSMA-617 in the intratibial LNCaP xenograft model of bone metastatic prostate cancer
    Scholz, Arne
    Knuuttila, Matias
    Zdrojewska, Justyna
    Suominen, Mari I.
    Alhoniemi, Esa
    Schatz, Christoph A.
    Zitzmann-Kolbe, Sabine
    Kakonen, Sanna-Maria
    Hagemann, Urs B.
    CANCER RESEARCH, 2023, 83 (07)
  • [23] Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).
    Hummel, Horst-Dieter
    Kufer, Peter
    Gruellich, Carsten
    Deschler-Baier, Barbara
    Chatterjee, Manik
    Goebeler, Maria-Elisabeth
    Miller, Kurt
    De Santis, Maria
    Loidl, Wolfgang C.
    Buck, Andreas
    Wittemer-Rump, Sabine
    Koca, Goekben
    Boix, Oliver
    Doecke, Wolf-Dietrich
    Stienen, Sabine
    Sayehli, Cyrus
    Bargou, Ralf C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] PRECLINICAL ACTIVITY AND SAFETY PROFILE OF JANX007, A NOVEL PSMA-TARGETING TUMORACTIVATED T CELL ENGAGER FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    DiRaimondo, Thomas
    Budimir, Natalija
    Shenhav, Simon
    Wu, Hua
    Cicchini, Vanessa
    Jocic, Renee
    Ma, Lina
    Roup, Fabrece
    Campbell, Calvin
    Caffaro, Carolina
    Aerni, Hans
    Eskiocak, Ugur
    Godfrey, Wayne
    Winter, Charles
    Nasoff, Marc
    Gibson, Neil
    Campbell, David
    Salek-Ardakani, Shahram
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1376 - A1376
  • [25] A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
    Dorff, Tanya
    Horvath, Lisa G.
    Autio, Karen
    Bernard-Tessier, Alice
    Rettig, Matthew B.
    Machiels, Jean-Pascal
    Bilen, Mehmet A.
    Lolkema, Martijn P.
    Adra, Nabil
    Rottey, Sylvie
    Greil, Richard
    Matsubara, Nobuaki
    Tan, Daniel S. W.
    Wong, Alvin
    Uemura, Hiroji
    Lemech, Charlotte
    Meran, Johannes
    Yu, Youfei
    Minocha, Mukul
    Mccomb, Mason
    Penny, Hweixian Leong
    Gupta, Vinita
    Hu, Xuguang
    Jurida, Gabor
    Kouros-Mehr, Hosein
    Janat-Amsbury, Margit M.
    Eggert, Tobias
    Tran, Ben
    CLINICAL CANCER RESEARCH, 2024, 30 (08) : 1488 - 1500
  • [26] PSMA-targeted alpha therapies inhibit tumor growth in xenograft models of visceral and bone metastatic castration-resistant prostate cancer
    Schatz, Christoph
    Suominen, Mari
    Knuuttila, Matias
    Zitzmann-Kolbe, Sabine
    Zdrojewska, Justyna
    Rissanen, Jukka
    Kakonen, Sanna-Maria
    Hagemann, Urs
    Scholz, Arne
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [27] Organic melanin nanoparticles targeting prostate-specific membrane antigen (PSMA) and multimodality imaging for human prostatic cancer xenograft model
    Xia, L.
    Cheng, Z.
    Zhu, H.
    Yang, Z.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S112 - S113
  • [28] The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
    Deegen, Petra
    Thomas, Oliver
    Nolan-Stevaux, Olivier
    Li, Shyun
    Wahl, Joachim
    Bogner, Pamela
    Aeffner, Famke
    Friedrich, Matthias
    Liao, Michael Z.
    Matthes, Katja
    Rau, Doris
    Rattel, Benno
    Raum, Tobias
    Kufer, Peter
    Coxon, Angela
    Bailis, Julie M.
    CLINICAL CANCER RESEARCH, 2021, 27 (10) : 2928 - 2937
  • [29] Initial clinical study results of 68Ga/177Lu-NYM032, a new generation of PSMA-targeting theranostic radiopharmaceuticals, in patients with metastatic prostate cancer
    He, H.
    Wang, Y.
    Mi, Y.
    Yan, C.
    Fang, P.
    Eng, W.
    Fu, H.
    Yu, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S180 - S181
  • [30] A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [177Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial
    Shin, Dongho
    Ha, Seunggyun
    Hyun, O. Joo
    Rhew, Seung Ah
    Yoon, Chang Eil
    Kwon, Hyeok Jae
    Moon, Hyong Woo
    Park, Yong Hyun
    Park, Sonya Youngju
    Park, Chansoo
    Chi, Dae Yoon
    Yoo, Ie Ryung
    Lee, Ji Youl
    CANCERS, 2022, 14 (24)
12345